Oligogenic inheritance in severe adult obesity.


Journal

International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108

Informations de publication

Date de publication:
31 Jan 2024
Historique:
received: 07 12 2022
accepted: 17 01 2024
revised: 13 11 2023
medline: 1 2 2024
pubmed: 1 2 2024
entrez: 31 1 2024
Statut: aheadofprint

Résumé

The genetic architecture of extreme non-syndromic obesity in adults remains to be elucidated. A range of genes are known to cause monogenic obesity, but even when pathogenic mutations are present, there may be variable penetrance. Whole-exome sequencing (WES) was carried out on a 15-year-old male proband of Pakistani ancestry who had severe obesity. This was followed by family segregation analysis, using Sanger sequencing. We also undertook re-analysis of WES data from 91 unrelated adults with severe obesity (86% white European ancestry) from the Personalised Medicine for Morbid Obesity (PMMO) cohort, recruited from the UK National Health Service. We identified an oligogenic mode of inheritance of obesity in the proband's family-this provided the impetus to reanalyze existing sequence data in a separate dataset. Analysis of PMMO participant data revealed two further patients who carried more than one rare, predicted-deleterious mutation in a known monogenic obesity gene. In all three cases, the genes involved had known autosomal dominant inheritance, with incomplete penetrance. Oligogenic inheritance may explain some of the variable penetrance in Mendelian forms of obesity. We caution clinicians and researchers to avoid confining sequence analysis to individual genes and, in particular, not to stop looking when the first potentially-causative mutation is found.

Sections du résumé

BACKGROUND/OBJECTIVE OBJECTIVE
The genetic architecture of extreme non-syndromic obesity in adults remains to be elucidated. A range of genes are known to cause monogenic obesity, but even when pathogenic mutations are present, there may be variable penetrance.
METHODS METHODS
Whole-exome sequencing (WES) was carried out on a 15-year-old male proband of Pakistani ancestry who had severe obesity. This was followed by family segregation analysis, using Sanger sequencing. We also undertook re-analysis of WES data from 91 unrelated adults with severe obesity (86% white European ancestry) from the Personalised Medicine for Morbid Obesity (PMMO) cohort, recruited from the UK National Health Service.
RESULTS RESULTS
We identified an oligogenic mode of inheritance of obesity in the proband's family-this provided the impetus to reanalyze existing sequence data in a separate dataset. Analysis of PMMO participant data revealed two further patients who carried more than one rare, predicted-deleterious mutation in a known monogenic obesity gene. In all three cases, the genes involved had known autosomal dominant inheritance, with incomplete penetrance.
CONCLUSION CONCLUSIONS
Oligogenic inheritance may explain some of the variable penetrance in Mendelian forms of obesity. We caution clinicians and researchers to avoid confining sequence analysis to individual genes and, in particular, not to stop looking when the first potentially-causative mutation is found.

Identifiants

pubmed: 38297031
doi: 10.1038/s41366-024-01476-9
pii: 10.1038/s41366-024-01476-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23:120–33.
doi: 10.1038/s41576-021-00414-z pubmed: 34556834
Bouchard C. Genetics of obesity: what we have learned over decades of research. Obesity. 2021;29:802–20.
doi: 10.1002/oby.23116 pubmed: 33899337
Manara E, Paolacci S, D’Esposito F, Abeshi A, Ziccardi L, Falsini B, et al. Mutation profile of BBS genes in patients with Bardet–Biedl syndrome: an Italian study. Ital J Pediatr. 2019;45:72.
doi: 10.1186/s13052-019-0659-1 pubmed: 31196119 pmcid: 6567512
Mukherjee S, Cogan JD, Newman JH, Phillips JA 3rd, Hamid R, Undiagnosed Diseases Network, et al. Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. Am J Hum Genet. 2021;108:1946–63.
doi: 10.1016/j.ajhg.2021.08.010 pubmed: 34529933 pmcid: 8546038
Gifford CA, Ranade SS, Samarakoon R, Salunga HT, de Soysa T, Huang Y, et al. Oligogenic inheritance of a human heart disease involving a genetic modifier. Science. 2019;364:865–70.
doi: 10.1126/science.aat5056 pubmed: 31147515 pmcid: 6557373
Schaaf CP, Sabo A, Sakai Y, Crosby J, Muzny D, Hawes A, et al. Oligogenic heterozygosity in individuals with high-functioning autism spectrum disorders. Hum Mol Genet. 2011;20:3366–75.
doi: 10.1093/hmg/ddr243 pubmed: 21624971 pmcid: 3153303
Hoefele J, Wolf MT, O’Toole JF, Otto EA, Schultheiss U, Dêschenes G, et al. Evidence of oligogenic inheritance in nephronophthisis. J Am Soc Nephrol. 2007;18:2789–95.
doi: 10.1681/ASN.2007020243 pubmed: 17855640
Heyne HO, Karjalainen J, Karczewski KJ, Lemmelä SM, Zhou W, FinnGen, Havulinna AS, et al. Mono- and biallelic variant effects on disease at biobank scale. Nature. 2023;613:519–25.
doi: 10.1038/s41586-022-05420-7 pubmed: 36653560 pmcid: 9849130
NIHR. Personalise Medicine for Morbid Obesity. UK Clinical Trials Gateway. 2012.
Doche ME, Bochukova EG, Su HW, Pearce LR, Keogh J, Henning E, et al. Human SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin Invest. 2012;122:4732–6.
doi: 10.1172/JCI62696 pubmed: 23160192 pmcid: 3533535
Stessman HAF, Willemsen MH, Fenckova M, Penn O, Hoischen A, Xiong B, et al. Disruption of POGZ is associated with intellectual disability and autism spectrum disorders. Am J Hum Genet. 2016;98:541–52.
doi: 10.1016/j.ajhg.2016.02.004 pubmed: 26942287 pmcid: 4890241
White J, Beck CR, Harel T, Posey JE, Jhangiani S, Tang S, et al. POGZ truncating alleles cause syndromic intellectual disability. Genome Med. 2016;8:3.
doi: 10.1186/s13073-015-0253-0 pubmed: 26739615 pmcid: 4702300
Fitzgerald TW, Gerety SS, Jones WD, van Kogelenberg M, King DA, McRae J, et al. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2014;519:223–8.
pmcid: 5955210
Nozawa RS, Nagao K, Masuda HT, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of HP1α from mitotic chromosome arms through Aurora B activation. Nature Cell Biology. 2010;12:719–27.
doi: 10.1038/ncb2075 pubmed: 20562864
Ye Y, Cho MT, Retterer K, Alexander N, Ben-Omran T, Al-Mureikhi M, et al. De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly. Cold Spring Harb Mol Case Stud. 2015;1:a000455.
doi: 10.1101/mcs.a000455 pubmed: 27148570 pmcid: 4850885
Laget S, Joulie M, Le Masson F, Sasai N, Christians E, Pradhan S, et al. The human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind methylated DNA. PLoS One. 2010;5:e11982.
doi: 10.1371/journal.pone.0011982 pubmed: 20700456 pmcid: 2917364
Talkowski ME, Mullegama SV, Rosenfeld JA, van Bon BW, Shen Y, Repnikova E, et al. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet. 2011;89:551–63.
doi: 10.1016/j.ajhg.2011.09.011 pubmed: 21981781 pmcid: 3188839
Mullegama SV, Elsea SH. Clinical and molecular aspects of MBD5-associated neurodevelopmental disorder (MAND). Eur J Hum Genet. 2016;24:1235–43.
doi: 10.1038/ejhg.2016.35 pubmed: 27222293 pmcid: 4989212
Hodge JC, Mitchell E, Pillalamarri V, Toler TL, Bartel F, Kearney HM, et al. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol Psychiatry. 2014;19:368–79.
doi: 10.1038/mp.2013.42 pubmed: 23587880
Mullegama SV, Pugliesi L, Burns B, Shah Z, Tahir R, Gu Y, et al. MBD5 haploinsufficiency is associated with sleep disturbance and disrupts circadian pathways common to Smith-Magenis and fragile X syndromes. Eur J Hum Genet. 2015;23:781–9.
doi: 10.1038/ejhg.2014.200 pubmed: 25271084
Shichiji M, Ito Y, Shimojima K, Nakamu H, Oguni H, Osawa M, et al. A cryptic microdeletion including MBD5 occurring within the breakpoint of a reciprocal translocation between chromosomes 2 and 5 in a patient with developmental delay and obesity. Am J Med Genet A. 2013;161A:850–5.
doi: 10.1002/ajmg.a.35768 pubmed: 23494922
Marco EJ, Aitken AB, Nair VP, da Gente G, Gerdes M, Bologlu L, et al. Burden of de novo mutations and inherited rare single nucleotide variants in children with sensory processing dysfunction. BMC Med Genomics. 2018;11:50.
doi: 10.1186/s12920-018-0362-x pubmed: 29801487 pmcid: 5970458
Han JY, Jang W, Park J, Kim M, Kim Y, Lee I, et al. Diagnostic approach with genetic tests for global developmental delay and/or intellectual disability: single tertiary center experience. Ann Hum Genet. 2018;83:115–23.
doi: 10.1111/ahg.12294 pubmed: 30402882
Tadros S, Wang R, Waters JJ, Waterman C, Collins A, Collinson M, et al. Inherited 2q23.1 microdeletions involving the MBD5 locus. Mol Genet Genomic Med. 2017;5:608–13.
doi: 10.1002/mgg3.316 pubmed: 28944244 pmcid: 5606852
Woodbury-Smith M, Nicolson R, Zarrei M, Yuen RKC, Walker S, Howe J, et al. Variable phenotype expression in a family segregating microdeletions of the NRXN1 and MBD5 autism spectrum disorder susceptibility genes. NPJ Genom Med. 2017;2:17.
doi: 10.1038/s41525-017-0020-9 pubmed: 28649445 pmcid: 5482711
Ishizuka K, Kimura H, Yoshimi A, Banno M, Kushima I, Uno Y, et al. Investigation of single-nucleotide variants in MBD5 associated with autism spectrum disorders and schizophrenia phenotypes. Nagoya J Med Sci. 2016;78:465–74.
pubmed: 28008202 pmcid: 5159472
Pettersson M, Viljakainen H, Loid P, Mustila T, Pekkinen M, Armenio M, et al. Copy number variants are enriched in individuals with early-onset obesity and highlight novel pathogenic pathways. J Clin Endocrinol Metab. 2017;102:3029–39.
doi: 10.1210/jc.2017-00565 pubmed: 28605459
Pearce LR, Joe R, Doche ME, Su HW, Keogh J, Henning E, et al. Functional characterization of obesity-associated variants involving the alpha and beta isoforms of human SH2B1. Endocrinology. 2014;155:3219–26.
doi: 10.1210/en.2014-1264 pubmed: 24971614 pmcid: 4138566
Papadimitriou S, Gazzo A, Versbraegen N, Nachtegael C, Aerts J, et al. Predicting disease-causing variant combinations. Proc Natl Acad Sci USA. 2019;116:11878–87.
doi: 10.1073/pnas.1815601116 pubmed: 31127050 pmcid: 6575632
Renaux A, Papadimitriou S, Versbraegen N, Nachtegael C, Boutry S, Nowé A, et al. ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations. Nucleic Acids Res. 2019;47:W93–W8.
doi: 10.1093/nar/gkz437 pubmed: 31147699 pmcid: 6602484
Alsters SI, Goldstone AP, Buxton JL, Zekavati A, Sosinsky A, Yiorkas A, et al. Truncating homozygous mutation of carboxypeptidase E (CPE) in a morbidly obese female with type 2 diabetes mellitus, intellectual disability and hypogonadotrophic hypogonadism. PLoS ONE. 2015;10:e0131417.
doi: 10.1371/journal.pone.0131417 pubmed: 26120850 pmcid: 4485893
An JY, Cristino AS, Zhao Q, Edson J, Williams SM, Ravine D, et al. Towards a molecular characterization of autism spectrum disorders: an exome sequencing and systems approach. Transl Psychiatry. 2014;4:e394.
doi: 10.1038/tp.2014.38 pubmed: 24893065 pmcid: 4080319

Auteurs

Sumaya Almansoori (S)

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. s.almansoori15@imperial.ac.uk.
Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK. s.almansoori15@imperial.ac.uk.
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates. s.almansoori15@imperial.ac.uk.
Genome Center, Department of Forensic Science and Criminology, Dubai Police GHQ, Dubai, United Arab Emirates. s.almansoori15@imperial.ac.uk.

Suzanne I Alsters (SI)

South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK.

Andrianos M Yiorkas (AM)

Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.

Nikman Adli Nor Hashim (NA)

Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Centre for Drug Research in Systems Biology, Structural Bioinformatics and Human Digital Imaging (CRYSTAL), Universiti Malaya, Kuala Lumpur, 50603, Malaysia.

Robin G Walters (RG)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.
MRC Population Health Research Unit, University of Oxford, Oxford, UK.

Harvinder S Chahal (HS)

Imperial Weight Centre, Imperial College Healthcare NHS Trust, St Mary's Hospital, Praed Street, London, W2 1NY, UK.
Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Campus, Hammersmith Hospital, 6th Floor Commonwealth Building, Du Cane Road, London, W12 0NN, UK.

Sanjay Purkayastha (S)

Department of Surgery and Cancer, Imperial College London, London, UK.

Nader Lessan (N)

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Imperial College London Diabetes Centre Abu Dhabi, Abu Dhabi, United Arab Emirates.

Alexandra I F Blakemore (AIF)

Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, London, UK.
College of Medicine, Nursing, and Health Science, University of Galway, Galway, Republic of Ireland.

Classifications MeSH